General Information
Novo Nordisk NN2211-4232
NN2211-4232/ LIRA PRIME - Efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a primary care setting
| Protocol | NN2211-4232 |
|---|---|
| Identifier | |
| UID | dfec28a5-72e9-4034-b6e3-8a9b7fc1b52e |
| Status | Done - Archived |
| Phase | 4 |
| Category | Diabetes Type 2 |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2015-09-25 15:25 |
| Last Updated | 2015-09-25 15:25 |
Description
No description provided.
Comment
CRI
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2016-04-06 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2016-02-17 | No |
| PI Meeting Start | 2016-03-09 | No |
| PI Meeting End | 2016-03-11 | No |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2019-10-16 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Pereira, Cynthia | CPereira | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Novo Nordisk |
|---|---|
| Division | Novo Nordisk |
| Team | Novo Nordisk |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
